Asensus Surgical — SafeStitch Medical — Q3 2013 Earnings Presentation
23 slides from Asensus Surgical's earnings presentation, Nov 18, 2013

Slide 1: Advancing Surgery Through Innovation
Advancing Surgery Through Innovation Exhibit 99.3

Slide 2: Cautionary Statement
Cautionary Statement 2 Any statements contained in this presentation that do not describe historical facts, including statements about the beliefs and expectations of SafeStitch Medical, Inc. (“SafeStitch”) and TransEnterix, Inc. (“TransEnterix”), may constitute forward-looking statements as that te

Slide 3: Financial Overview
3 Financial Overview Joe Slattery Executive Vice President & CFO

Slide 4: Advancing Surgery Through Innovation
Advancing Surgery Through Innovation

Slide 5: Investment Highlights
Investment Highlights Focus Technology Solution Market Team • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Large addressable market – ~2M US procedures • Strong management team • Cost effective • Broad procedure applica

Slide 6: Company History
Company History 6 2006 2009 2010 2012 2013 • TransEnterix founded • FDA 510(K) clearance for Spider Surgical System • CE Mark clearance and release of Spider Surgical System • >3,000 SPIDER cumulative procedures performed to date • Began SurgiBot development • SurgiBot preclinical labs • Merger with

Slide 7: Merger with SafeStitch Medical
Merger with SafeStitch Medical 7 • Transaction closed on September 4, 2013 • About SafeStitch – Publicly-traded, development stage medical device company (OTCBB: SFES) – Obesity and GERD-focused, flexible endoluminal instrumentation • Board and investors with demonstrated success in leading high-gro

Slide 8: Surgical Progress = Less Invasive
Surgical Progress = Less Invasive 8 Open Surgery Rigid Laparoscopy (1989) Flexible Laparoscopy (2010)

Slide 9: Spider Surgical System Enabling Flexible Laparoscopy
Spider Surgical System Enabling Flexible Laparoscopy 9 • • • • • • Internal (intra-abdominal) triangulation Flexible, articulating instruments for dissection and retraction True left/right instrumentation Lower profile port of access Over 3,000 procedures performed Broad procedural mix

Slide 10: Innovative, Minimally Invasive Robotic Platform SurgiBot
Innovative, Minimally Invasive Robotic Platform SurgiBot TM

Slide 11: Benefits of Surgical Robotics
Benefits of Surgical Robotics 11 Benefits of Surgical Robotics Improved dissection and retraction strength Enhanced precision and control Improved surgeon ergonomics Advanced visualization

Slide 12: SurgiBot First Patient-side Robotic Platform
Confidential 12 SurgiBot First Patient-side Robotic Platform Positioning Arm Cart Endodrive Flex Instruments 3DHD Optics

Slide 13: SurgiBot First Patient-side Robotic Platform
SurgiBot First Patient-side Robotic Platform 13 Surgeon scrubbed-in Flexible, articulating channels & instruments Flexible & steerable 3DHD Small, mobile platform Easily repositioned for multi- quadrant surgery Cost effective platform

Slide 14: Benefits to Key Stakeholders
14 Benefits to Key Stakeholders Surgeons • Precision of robotic surgery • Advanced 3D visualization • Scrubbed-in patient-side • Ergonomics/reduced fatigue Hospitals and Surgical Centers • Attractive ROI for many health care facilities, relative to competing robotic platforms • Strategic asset for s

Slide 15: Large Addressable Market
Large Addressable Market 15 1,566 2,054 930 458 Additionally over surgery centers in US 5,000 Source: CDC Over 5,000 Hospitals in the United States # of Beds Under 50 50-200 200-400 Over 400

Slide 16: Hospital Market Opportunity
Hospital Market Opportunity Confidential 16 Hospitals without Robotic Capability Hospitals with Robotic Capability • Current robotic offerings are not cost effective • Price • Procedure volume • Surgery centers – untapped market for robotics • Large underpenetrated OUS opportunity • Invested in the

Slide 17: Procedure Market Opportunity
17 Bariatric Surgery Cholecystectomy Colorectal Gynecology/Urology Procedure Market Opportunity Targeted US Procedures 160K 1,140K 363K 230K Source: Millennium Research Group US Markets Laparoscopic Devices 2014 Note: Company Estimate of Outside US addressable market = US opportunity ~2M US Laparosc

Slide 18: Recurring Revenue Model
Recurring Revenue Model 18 Capital Equipment Service Instruments and Accessories

Slide 19: Commercial Pathway
Commercial Pathway 19 2013 2014 2015 • Design & Pre-clinical Testing • Pre-submission FDA Meeting • First Human Procedures • Regulatory Submissions • Regulatory Clearances • Global Launch

Slide 20: Management Team
Management Team 20 Prior Experience Todd M. Pope President and Chief Executive Officer Joe Slattery EVP and Chief Financial Officer Richard Mueller Chief Operating Officer Mohan Nathan Vice President of Global Marketing Tammy Carrea Vice President, Quality and Regulatory Affairs

Slide 21: Board of Directors and Healthcare Investors
21 Board of Directors Healthcare Investors Board of Directors and Healthcare Investors • Phillip Frost, M.D. – CEO and Chairman of OPKO Health – Chairman of Teva Pharmaceuticals • Jane Hsiao, Ph.D., MBA – Former Chairman of SafeStitch – Vice Chairman and CTO of OPKO Health • Aftab Kherani, M.D. – Pr

Slide 22: Investment Highlights
Investment Highlights 22 Focus Technology Solution Market Team • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Large addressable market – ~2M US procedures • Strong management team • Cost effective • Broad procedure appl

Slide 23: Advancing Surgery Through Innovation
Advancing Surgery Through Innovation
Source: SEC EDGAR · 8-K filed Nov 18, 2013
More decks from Asensus Surgical Inc
Investor Presentation (June 2023)25 slides · Jun 5, 2023
Investor Day (February 2023)65 slides · Feb 21, 2023
40th Annual J.P. Morgan Healthcare Conference (January 2022)23 slides · Jan 13, 2022
Transenterix — Investor Day (February 2021)22 slides · Feb 23, 2021
TransEnterix — H.C. Wainwright 22nd Annual Global Investment Conference (September 2020)20 slides · Sep 15, 2020
TransEnterix — Q3 2019 Earnings Presentation25 slides · Nov 13, 2019